secwatch.observer — SEC 8-K summary
======================================

Issuer:     Chemomab Therapeutics Ltd. (CMMB)
CIK:        0001534248
Form:       8-K
Filed at:   2022-08-12T23:59:59+00:00
Accession:  0001178913-22-003072
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Chemomab Q2 net loss $6.2M, cash $51.8M; NASH topline due by year-end
---------------------------------------------------------------------

- Net loss $6.2M ($0.03/share) for Q2 2022 vs $2.8M loss in Q2 2021; R&D expense rose to $2.9M from $1.3M.
- Cash, equivalents and deposits $51.8M at June 30; runway expected through end of 2023.
- Phase 2 NASH trial completed treatment; topline safety and activity data expected before year-end 2022.
- Phase 2 PSC trial expanded to 93 patients across three dose cohorts; topline data anticipated H2 2024.
- Appointed Jill Quigley to board, Ilan Vaknin as VP R&D, and Christina Crater as VP Clinical Development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534248/000117891322003072/0001178913-22-003072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534248/000117891322003072/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001178913-22-003072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer